Tesamorelin vs Ipamorelin: Approved Drug vs Research Peptide, Compared on the Evidence

Written by Dr. Andrii Kaleniuk. Updated October 24, 2026.

Tesamorelin and ipamorelin both raise your own growth hormone, but they are not in the same category. Tesamorelin is an FDA-approved prescription drug (Egrifta) with Phase 3 trials showing it cuts deep belly fat by about 15% in adults with HIV, and a newer weekly-reconstituted version approved in 2025. Ipamorelin is an abandoned drug candidate with one short placebo-controlled trial, no approval anywhere, and an FDA listing as a compounding substance that may present significant safety risks. Both are banned by WADA. No trial has ever tested them together.

This comparison lays out how each works, what the human evidence actually shows for fat loss, muscle, recovery and sleep, the side effects and legal status of each as of October 2026, and who should avoid them. It does not include dosing, because tesamorelin's only established dose is for a medical condition and ipamorelin has none.

Tesamorelin is a synthetic version of growth-hormone-releasing hormone (GHRH), the signal the hypothalamus sends to the pituitary gland to release growth hormone. It is 44 amino acids long with a modification that stops it being broken down within minutes, so one injection produces a sustained release of the body's own GH and, downstream, IGF-1. Because it works through the normal feedback system, GH does not rise to the levels seen with GH injections.

It was developed by Theratechnologies for a specific problem: the buildup of visceral fat in people with HIV on antiretroviral therapy (lipodystrophy). FDA approved it as Egrifta in November 2010 for that indication, and in March 2025 approved Egrifta WR, a formulation reconstituted once a week and injected daily, which replaced the older daily-reconstitution product. We cover its fat-loss data in tesamorelin for fat loss.

Ipamorelin is a five-amino-acid peptide developed in the 1990s by Novo Nordisk as a growth hormone secretagogue. It mimics ghrelin, the hunger hormone, at the GHS-R1a receptor in the pituitary and hypothalamus, triggering a pulse of GH. Its selling point in animal studies was selectivity: unlike the older peptides GHRP-2 and GHRP-6, it raised GH without raising cortisol or ACTH, even at high doses.

Novo Nordisk later tested it in hospital patients for post-surgical bowel paralysis, and when that failed, development stopped. It has never been approved for anything. Everything sold today comes from peptide vendors or compounding pharmacies, and its reputation for muscle, recovery and sleep rests on theory and user reports. See ipamorelin for bodybuilding and ipamorelin side effects.

This is tesamorelin's home ground. In two Phase 3 trials published in 2010, 816 adults with HIV and excess abdominal fat received tesamorelin or placebo for 26 weeks. Visceral fat, measured by CT scan, fell by about 15% with tesamorelin and rose slightly with placebo; triglycerides fell and waist size shrank. When treatment stopped, the fat came back within six months, so the effect depends on continued use. A separate study found tesamorelin also reduced liver fat in people with HIV and fatty liver disease.

Whether that translates to people without HIV is less certain. The mechanism, raising GH and IGF-1 to mobilize visceral fat, is not HIV-specific, and small studies in the general population have shown similar directions of effect, but there is no Phase 3 trial of tesamorelin for ordinary belly fat, and the drug is not approved for it. Ipamorelin, by contrast, has no human fat-loss data at all. Any claim that it "burns fat" is extrapolated from what GH does in general.

Neither peptide has been shown to build muscle in a controlled human trial. Tesamorelin trials recorded a small increase in lean mass alongside fat loss, which is consistent with higher GH and IGF-1, but strength and performance were not measured. The broader GH literature is sobering: a 2008 systematic review of GH in healthy adults found more lean mass but no gain in strength or exercise capacity, with more swelling and fatigue. Ipamorelin's recovery and muscle reputation comes from forums and from clinics that sell it. We examine the stacking claims in CJC-1295 + ipamorelin for muscle growth and CJC-1295 for muscle growth.

Ipamorelin is often recommended for sleep on the theory that GH pulses during deep sleep and ghrelin mimetics given at night amplify them. Studies of GHRPs and ghrelin do show more slow-wave sleep in some settings, but no trial has tested ipamorelin for sleep quality. Tesamorelin has not been studied for sleep either. Both effects, if real, are modest and indirect.

Tesamorelin's side effects are known because they were recorded in trials: joint pain (about 13%), swelling of the arms and legs, muscle aches, tingling, injection-site redness and itching, and increases in blood sugar. It can raise IGF-1 above the normal range, so levels are monitored, and it is contraindicated in active cancer, pregnancy and pituitary disease. Rare allergic reactions have been reported. It should not be used by people with diabetes without close monitoring.

Ipamorelin's trial data cover one week in hospital patients, where it was no worse than placebo. Beyond that, users report headache, flushing, dizziness, nausea, water retention, tingling, increased hunger and injection-site lumps. The deeper concerns are the ones that apply to any sustained GH increase: fluid retention, carpal tunnel symptoms, insulin resistance and theoretical effects on existing cancers, none of which has been studied for ipamorelin over months. Add to that the product-quality problem: vendor ipamorelin is not checked for purity, sterility or dose.

Clinics and vendors offer the combination on the logic that a GHRH analogue and a ghrelin mimetic act on different receptors and produce a bigger GH pulse together than either alone. That synergy is real in the sense that GHRH plus GHRP combinations have been shown to amplify GH release in physiology studies. But no trial has tested tesamorelin with ipamorelin for any outcome, in anyone. Combining a prescription drug with an unapproved peptide means stacking a documented side-effect profile on top of an unknown one, and it is not something any label or guideline supports. Our tesamorelin vs CJC-1295 vs ipamorelin guide covers the three-way comparison people usually mean.

Tesamorelin is an approved drug that does one thing well: it reduces visceral fat in people with HIV lipodystrophy, with documented side effects and a prescription-only route. Ipamorelin is an abandoned drug candidate with a selective, well-tolerated GH-release profile over one week and no evidence for any of the benefits it is sold for. Comparing them as if they were two brands of the same product misleads. If you have a medical reason for tesamorelin, a doctor can prescribe it; if you are looking at ipamorelin for muscle, recovery or sleep, you are looking at a product whose benefits, risks and contents are all unverified.

This article is for information only. It is not medical advice and does not recommend using either substance outside a doctor's care.